ResMed sues Fisher & Paykel for Patent Infringement


Fisher & Paykel’s stock got dragged down 3.069% to $14.530 on getting hit by patent infringement allegation filed by California-based ResMed.

In a recent update it was revealed that on Saturday 1 September 2018 medical equipment company ResMed has filed a lawsuit with the US International Trade Commission (ITC) and US District Court against the patented technology of New Zealand-based Fisher & Paykel Healthcare.

Fisher & Paykel healthcare (ASX: FPH) is accused of infringement in relation to Eson and Simplus range of patented masks which are used in the treatment of obstructive sleep apnea. Innovator in sleep apnea and respiratory care, ResMed seeks an ITC order to stop the import and sale of these products into the US. It also seeks for monetary damages in the US district court. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

But following to the petition filed by ResMed, Fisher & Paykel Healthcare announced today that it will contest patent allegations made against it. In the light of significant legal cost to be incurred in the contest of these claims, the company has released updated FY19 guidance.

The NPAT for the 2019 financial year is now expected to be in the range of approximately NZ$205 million to NZ$210 million. Although FY19 half-year result guidance remains the same, full year earning guidance has been updated to NZ$215 million.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report